-
Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024
- Mónica López-Lacort1,2,* , Cintia Muñoz-Quiles1,2,* , Ainara Mira-Iglesias1,2 , F Xavier López-Labrador2,3,4 , Beatriz Mengual-Chuliá2,3 , Carlos Fernández-García1 , Mario Carballido-Fernández5,6 , Ana Pineda-Caplliure7 , Juan Mollar-Maseres8 , Maruan Shalabi Benavent9 , Francisco Sanz-Herrero10 , Matilde Zornoza-Moreno11 , Jaime Jesús Pérez-Martín11 , Santiago Alfayate-Miguelez11 , Rocío Pérez Crespo12 , Encarnación Bastida Sánchez12 , Ana Isabel Menasalvas-Ruiz13 , Mª Cinta Téllez-González13 , Samuel Esquiva Soto13 , Carlos Del Toro Saravia14 , Iván Sanz-Muñoz15 , José María Eiros15 , Vanesa Matías Del Pozo16 , Marina Toquero-Asensi16 , Eliseo Pastor-Villalba17 , José Antonio Lluch-Rodrigo17 , Javier Díez-Domingo1,2,18 , Alejandro Orrico-Sánchez1,2,18
-
View Affiliations Hide AffiliationsAffiliations: 1 Vaccine Research Department, Fisabio-Public Health, Valencia, Spain 2 CIBERESP, Instituto de Salud Carlos III, Madrid, Spain 3 Virology Laboratory, Fisabio-Public Health, Valencia, Spain 4 Department of Microbiology and Ecology, Medical School, University of Valencia, Valencia, Spain 5 Hospital General Universitario de Castellón, Castellón, Spain 6 Medicine Department, Universidad CEU Cardenal Herrera, Castellón de la Plana, Spain 7 Hospital Universitario Dr. Peset, Valencia, Spain 8 Hospital Universitario La Fe, Valencia, Spain 9 Hospital Marina Baixa, Alicante, Spain 10 Hospital General Universitario, Valencia, Spain 11 Murcia Health Council, Murcia, Spain 12 Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain 13 Hospital General Universitario Santa Lucía, Murcia, Spain 14 Hospital Rafael Méndez, Murcia, Spain 15 National Influenza Centre, Valladolid, Spain 16 Hospital Clínico, Valladolid, Spain 17 Dirección General de Salud Pública, Valencia, Spain 18 Catholic University of Valencia, Valencia, Spain * These authors contributed equally to this article and share first authorship.Mónica López-Lacortmonica.lopez fisabio.es
-
View Citation Hide Citation
Citation style for this article: López-Lacort Mónica, Muñoz-Quiles Cintia, Mira-Iglesias Ainara, López-Labrador F Xavier, Mengual-Chuliá Beatriz, Fernández-García Carlos, Carballido-Fernández Mario, Pineda-Caplliure Ana, Mollar-Maseres Juan, Shalabi Benavent Maruan, Sanz-Herrero Francisco, Zornoza-Moreno Matilde, Pérez-Martín Jaime Jesús, Alfayate-Miguelez Santiago, Pérez Crespo Rocío, Bastida Sánchez Encarnación, Menasalvas-Ruiz Ana Isabel, Téllez-González Mª Cinta, Esquiva Soto Samuel, Del Toro Saravia Carlos, Sanz-Muñoz Iván, Eiros José María, Matías Del Pozo Vanesa, Toquero-Asensi Marina, Pastor-Villalba Eliseo, Lluch-Rodrigo José Antonio, Díez-Domingo Javier, Orrico-Sánchez Alejandro. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. Euro Surveill. 2024;29(6):pii=2400046. https://doi.org/10.2807/1560-7917.ES.2024.29.6.2400046 Received: 19 Jan 2024; Accepted: 06 Feb 2024
- Previous Article
- Table of Contents
- Next Article
Abstract
The monoclonal antibody nirsevimab was at least 70% effective in preventing hospitalisations in infants with lower respiratory tract infections (LRTI) positive for respiratory syncytial virus (RSV) in Spain (Oct 2023–Jan 2024), where a universal immunisation programme began late September (coverage range: 79–99%). High protection was confirmed by two methodological designs (screening and test-negative) in a multicentre active surveillance in nine hospitals in three regions. No protection against RSV-negative LRTI-hospitalisations was shown. These interim results could guide public-health decision-making.
Article metrics loading...
Full text loading...
References
-
Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415-25. https://doi.org/10.1056/NEJMoa1913556 PMID: 32726528
-
Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837-46. https://doi.org/10.1056/NEJMoa2110275 PMID: 35235726
-
Simões EAF, Madhi SA, Muller WJ, Atanasova V, Bosheva M, Cabañas F, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023;7(3):180-9. https://doi.org/10.1016/S2352-4642(22)00321-2 PMID: 36634694
-
Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023;389(26):2425-35. https://doi.org/10.1056/NEJMoa2309189 PMID: 38157500
-
Ernst C, Bejko D, Gaasch L, Hannelas E, Kahn I, Pierron C, et al. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg. Euro Surveill. 2024;29(4):2400033. https://doi.org/10.2807/1560-7917.ES.2024.29.4.2400033 PMID: 38275017
-
Martinón-Torres F, Mirás-Carballal S, Durán-Parrondo C. Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023. Euro Surveill. 2023;28(49):2300606. https://doi.org/10.2807/1560-7917.ES.2023.28.49.2300606 PMID: 38062942
-
Mira-Iglesias A, Demont C, López-Labrador FX, Mengual-Chuliá B, García-Rubio J, Carballido-Fernández M, et al. Role of age and birth month in infants hospitalized with RSV-confirmed disease in the Valencia Region, Spain. Influenza Other Respir Viruses. 2022;16(2):328-39. https://doi.org/10.1111/irv.12937 PMID: 34821055
-
European Centre for Disease Prevention and Control (ECDC). Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARSCoV-2, version 1.0. Stockholm: ECDC; 2021. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Core-protocol-for-ECDC-studies-of-COVID-19-vaccine-effectiveness-against-hospitalisation-with-SARI.pdf
-
Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013;31(17):2165-8. https://doi.org/10.1016/j.vaccine.2013.02.053 PMID: 23499601
-
Sullivan SG, Feng S, Cowling BJ. Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. Expert Rev Vaccines. 2014;13(12):1571-91. https://doi.org/10.1586/14760584.2014.966695 PMID: 25348015
-
Ladhani SN, Andrews N, Parikh SR, Campbell H, White J, Edelstein M, et al. Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309-17. https://doi.org/10.1056/NEJMoa1901229 PMID: 31971676
-
Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388(10061):2775-82. https://doi.org/10.1016/S0140-6736(16)31921-3 PMID: 28100432
-
Wildenbeest JG, Billard MN, Zuurbier RP, Korsten K, Langedijk AC, van de Ven PM, et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med. 2023;11(4):341-53. https://doi.org/10.1016/S2213-2600(22)00414-3 PMID: 36372082
-
Muñoz-Quiles C, López-Lacort M, Úbeda-Sansano I, Alemán-Sánchez S, Pérez-Vilar S, Puig-Barberà J, et al. Population-based Analysis of Bronchiolitis Epidemiology in Valencia, Spain. Pediatr Infect Dis J. 2016;35(3):275-80. https://doi.org/10.1097/INF.0000000000000993 PMID: 26658376
Data & Media loading...
Supplementary data
-
-
Supplement
-